Both in Pharmaceuticals
Aurinia Pharmaceuticals vs Zymeworks
Over the past year AUPH returned +29.4% and ZYME returned +63.4%; their daily moves had a correlation of 0.24.
AUPH +29.4% ZYME +63.4%Growth of $1, one year, split-adjusted
| Metric | AUPH | ZYME |
|---|---|---|
| Price | $16.56 | $30.13 |
| Market cap | $2.22B | $2.17B |
| Today | +2.60% | +3.93% |
| 1 month | +5.3% | +15.0% |
| 6 months | +3.2% | +12.9% |
| Year to date | +3.8% | +14.4% |
| 1 year | +25.7% | +57.9% |
| Revenue growth (YoY) | +13.9% | −90.6% |
| Gross margin | 90.1% | 100.0% |
| Net margin | 37.9% | −980.8% |
| P/E (TTM) | 7.1× | — |
| Price / sales | 6.9× | 58.3× |
| Net cash | $431.7M | $270.7M |
| Dividend yield | — | — |
| Volatility (60d) | 30.3% | 46.8% |
| Short % of float | 7.3% | 12.5% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).